Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 09, 2023 16:05 ET
|
Morphic Therapeutic
WALTHAM, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
August 03, 2023 07:05 ET
|
Morphic Therapeutic
-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Greater...
Morphic to Present at the Jefferies Global Healthcare Conference
June 06, 2023 16:05 ET
|
Morphic Therapeutic
WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference
May 12, 2023 08:30 ET
|
Morphic Therapeutic
WALTHAM, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis
May 11, 2023 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF) today announced the presentation of new preclinical data in the MORF-057 IBD development program that are...
Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 05, 2023 10:30 ET
|
Morphic Therapeutic
WALTHAM, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic...
Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering
May 03, 2023 00:13 ET
|
Morphic Therapeutic
WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious...
Morphic Therapeutic Announces Proposed Public Offering
May 02, 2023 16:02 ET
|
Morphic Therapeutic
WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious...
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
April 25, 2023 07:00 ET
|
Morphic Therapeutic
-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in the Robarts Histopathology Index (RHI) Score- -MORF-057 achieves 25.7% clinical...
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
April 25, 2023 06:59 ET
|
Morphic Therapeutic
-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures with no...